Zobrazeno 1 - 10
of 332
pro vyhledávání: '"J.W.R. Nortier"'
Autor:
J.F.R. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, A. Makris, J.W.R. Nortier, K. Possinger, L.-E. Rutqvist
Publikováno v:
Опухоли женской репродуктивной системы, Vol 0, Iss 1, Pp 33-40 (2014)
For many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as firs
Externí odkaz:
https://doaj.org/article/d725b19995d34eca907003a2bf7065a4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Suzan Vrijaldenhoven, Joan B. Heijns, Mpg Vreeswijk, H de Graaf, S de Groot, Marij J. P. Welters, J.W.R. Nortier, Valter D. Longo, E van Leeuwen-Stok, R. T. Lugtenberg, J.E.A. Portielje, Hanno Pijl, LW Kessels, Arnold Baars, E. Meershoek-Klein Kranenbarg, J.J.M. van der Hoeven, Vthbm Smit, Ilina Ehsan, Hein Putter, A.L.T. Imholz, AJ van de Wouw, Judith R. Kroep, M. Duijm-de Carpentier
Publikováno v:
Cancer Research. 79:P1-15
Background: Short term fasting (STF) protects from toxicity, while enhancing the efficacy of chemotherapy in cancer bearing mice and is a promising strategy to enhance the efficacy and tolerability of chemotherapy in humans. A specifically designed l
Autor:
Kunihiko Kobayashi, Kaoru Kubota, Hein Putter, Ayako Matsuda, Kazue Yamaoka, J.W.R. Nortier, S. R. S. Ramai, R. T. Lugtenberg, Kenichi Inoue, Maarten J. Fischer, Hans Gelderblom, Judith R. Kroep, F. de Jongh, Ad A. Kaptein, N.I. Weijl
Publikováno v:
Quality of Life Research
Quality of Life Research, 29(11), 2961-2975. SPRINGER
Quality of Life Research, 29(11), 2961-2975. SPRINGER
Purpose The diagnosis and treatment of cancer negatively affect patients’ physical, functional and psychological wellbeing. Patients’ needs for care cannot be addressed unless they are recognized by healthcare providers (HCPs). The use of quality
Autor:
J.W.R. Nortier, Judith R. Kroep, Cjh van de Velde, E.J.T. Rutgers, E.J. Blok, M. Duijm-de Carpentier, E. Meershoek-Klein Kranenbarg
Publikováno v:
Cancer Research. 78:P3-12
In the first clinical trial reports about extended endocrine therapy in early breast cancer, treatment compliance appeared as a major concern. Earlier, it was shown in the IDEAL trial that approximately 35% of all patients stopped therapy before the
Autor:
W. van de Water, Annette Hasenburg, Hein Putter, G.J. Liefers, J.W.R. Nortier, C. Markopoulos, L Dirix, Marloes G.M. Derks, Caroline Seynaeve, Esther Bastiaannet, N.A. de Glas, Daniel Rea, C.J.H. van de Velde, Johanneke E.A. Portielje
Publikováno v:
European Journal of Cancer, 99, 1-8. Elsevier Ltd.
European Journal of Cancer, 99, 1-8
European Journal of Cancer, 99, 1-8
Due to increasing life expectancy, patients with breast cancer remain at risk of dying due to breast cancer over a long time. This study aims to assess the impact of age on breast cancer mortality and other cause mortality 10 years after diagnosis.Po
Autor:
E. Meershoek-Klein Kranenbarg, J. van den Bosch, Cjh van de Velde, Judith R. Kroep, G.J. Liefers, A.E. van Leeuwen-Stok, Ejt Rutgers, E. Maartense, E.J. Blok, Hein Putter, M Duym-de Carpentier, J.W.R. Nortier
Publikováno v:
Cancer Research. 77:P2-09
The implementation of adjuvant aromatase inhibitors (AI) has contributed significantly to an ongoing improvement in survival of early breast cancer patients, but the impact of extended AI on toxicity after use in the initial 5 years has not yet been
Autor:
E. Meershoek-Klein Kranenbarg, E.J. Blok, A.E. van Leeuwen-Stok, J.W.R. Nortier, Ejt Rutgers, G.J. Liefers, Judith R. Kroep, E. Maartense, Cjh van de Velde, Hein Putter, J. van den Bosch
Publikováno v:
Cancer Research. 77:S1-04
Despite the success of adjuvant endocrine therapy in early breast cancer, approximately 50% of all recurrences still occur after the initial 5 years of follow-up. Earlier studies confirmed that endocrine therapy extension after 5 years of adjuvant ta
Autor:
C.C. Engels, Hein Putter, Robert Paridaens, E. Meershoek-Klein Kranenbarg, Cjh van de Velde, Annette Hasenburg, D.W. Rea, Jms Bartlett, E.J. Blok, P.J.K. Kuppen, J.W.R. Nortier, G.J. Liefers, Carine Seynaeve, Mgm Derks, Judith R. Kroep, C. Markopoulos
Publikováno v:
Cancer Research. 77:PD2-07
Optimal endocrine therapy for postmenopausal, hormone-receptor positive (HR+) early breast cancer remains a point of discussion. The Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase III trial showed no significant differences for disease free
Autor:
Peter J. K. Kuppen, Judith R. Kroep, S.H. van der Burg, G.J. Liefers, A. Charehbili, E. Meershoek-Klein Kranenbarg, C.J.H. van de Velde, A.F. de Groot, N.G. Dekker-Ensink, Hein Putter, Vthbm Smit, E.J. Blok, C.C. Engels, J.W.R. Nortier
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 175(3), 605-615
Breast Cancer Research and Treatment, 175(3), 605-615
Purpose Tumor-infiltrating lymphocytes (TILs) are associated with pathological complete response (pCR) and survival after neoadjuvant chemotherapy (NAC) in patients with early breast cancer. We investigated the prognostic and predictive role of TILs,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8204bc36a8f02f004de0a36da603b3bf
https://hdl.handle.net/1887/121312
https://hdl.handle.net/1887/121312